Management strategies: Prophylaxis, empirical and pre-emptive treatment and treatment of established invasive candidiasis in the critically ill non-neutropenic patient;Estrategias de tratamiento: Profilaxis, tratamiento empírico, precoz (anticipado) y dirigido de candidiasis invasora en el enfermo crítico no neutropénico

Revista Iberoamericana de Micologia

Volumn 23, Issue 1, 2006, Pages 35-38

  Palacio, Amalia Del ^a   Alhambra, Almudena ^a   Cuétara, Ma Soledad ^b  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b HOSPITAL SEVERO OCHOA   (Spain)

Author keywords

Empirical; Invasive candidiasis; Pre emptive therapy; Prophylaxis; Treatment

Indexed keywords

FLUCONAZOLE;

CANDIDIASIS; CRITICALLY ILL PATIENT; EMPIRICISM; HUMAN; LABORATORY DIAGNOSIS; NEUTROPENIA; PROPHYLAXIS; REVIEW; RISK MANAGEMENT;

EID: 32644432381     PISSN: 11301406     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1130-1406(06)70011-0     Document Type: Review

References (24)

1. Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F, Denning DW, Donnelly JP, Edwards JE, Erjavec Z, Fiere D, Lortholary O, Maertens J, Meis JF, Patterson TF, Ritter J, Selleslag D, Shah PM, Stevens DA, Walsh TJ; Invasive Fungal Infections Cooperative Group of the European Organization for Research and Treatment of Cancer; Mycoses Study Group of the National Institute of Allergy and Infectious Diseases, Defining opportunistic invasive fungal infection in inmunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7-14.
2. British Society for Antimicrobial Chemotherapy Working Party. Management of deep Candida infection in surgical and intensive care unit patients. Intensive Care Med 1994; 20: 522-528.
3. Calandra T, Marchetti O. Clinical trials of antifungal prophylaxis among patients undergoing surgery. Clin Infect Dis 2004; 39: 3193-3194.
4. De Waele JJ, Vogalaers D, Blot S, Colardyn F. Fungal infections in patients with severe acute pancreatitis and the use of prophylactic therapy. Clin Infect Dis 2003; 37: 208-213.
5. De Pauw BE, Patterson TF. Should consensus guidelines specific criteria for the diagnosis of invasive fungal infection be changed? Clin Infect Dis 2005; 41: S377-3380.
6. Dupont H, Bourichon A, Paugam-Burtz C, Mantz J, Desmonts JM. Can yeast isolation in peritoneal fluid be predicted in intensive care unit patients with peritonitis? Crit Care Med 2003; 31: 725-757.
7. Edwards JE Jr, Bodey GP, Bowden RA, Buchner T, de Pauw BE, Filler SG, Ghannoum MA, Glauser M, Herbrecht R, Kauffman CA, Kohno S, Martino P, Meunier F, Mori T, Pfaller MA, Rex JH, Rogers TR, Rubin RH, Solomkin J, Viscoli C, Walsh TJ, White M. Internatioanl Conference for the development of a consensus on the management and prevention of severe candidal infections. Clin Infect Dis 1997; 25: 43-59.
8. Eggimann P, Francioli P, Bille J, Schneider R, Wu MM, Chapuis G, Chiolero R, Pannatier A, Schilling J, Geroulanos S, Glauser MP, Calandra T. Fluconazole prophylaxis prevents intraabdominal candidiasis in high-risk surgical patients. Crit Care Med 1999; 27: 1066-1072.
9. Garbino J, Lew DP, Romand JA, Hugonnet S, Auckenthaler R, Pittet D. Prevention of severe Candida infections in non-neutropenic, high risk, critically ill patients: a randomized double-blind, placebo controlled trial in patients treated by selective digestive decontamination. Intensive Care Med 2002; 28: 1708-1717.
10. Jones BL, Mc Lintock LA. Impact of diagnostic markers on early antifungal therapy. Curr Opin Infect Dis 2003; 16: 521-526.
11. Lipsett PA. Clinical trials of antifungal prophylaxis among patients in surgical intensive care units: concepts and considerations. Clin Infect Dis 2004; 39: S193-S199.
12. Nguyen MH, Peacock JE Jr, Tanner DC, Morris AJ, Nguyen ML, Snydman DR, Wagener MM, Yu VL. Therapeutic approaches in patients with candidemia. Arch Inter Med 1995; 155: 2429-2435.
13. Nolla-Salas J, Sitges-Serra A, Leon-Gil C, Martinez-Gonzalez J, Leon-Regidor MA, Ibanez-Lucia P, Torres-Rodriguez JM. Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy. Int Care Med 1997; 23: 23-30.
14. Ostrosky-Zeichner L. Prophylaxis and treatment of invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis 2004; 23: 739-744.
15. Pappas PG, Rex JH, Sobel JD, Filler SG, Dismukes WE, Walsh TJ, Edwards JE; Infectious Diseases Society of America. Guidelines for treatment of candidiasis. Clin Infect Dis 2004; 38: 161-189.
16. Pelz RK, Hendrix CW, Swoboda SM, Diener-West M, Merz WG, Hammond J, Lipsett PA. Double-blind placebo controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Ann Surg 2001; 233: 542-548.
17. Powers JH. Issues in clinical trials of prophylaxis of fungal infections. Clin Infect Dis 2004; 39: S211-S217.
18. Quindós G, Moragues MD, Pontón J. Is there a role for antibody testing in the diagnosis of invasive candidiasis? Rev Iberoam Micol 2004; 21: 10-14.
19. Slotman GJ, Bourchard KW. Ketoconazole prevents Candida sepsis in critically ill surgical patients. Arch Surg 1987; 122: 147-151.
20. Rex JH, Sobel JD. Prophylactic antifungal therapy in the intensive care unit. Clin Infect Dis 2001; 32: 1191-1200.
21. Rex JH, Wingard JR, Wenzel R. The design of clinical trials that evaluate antifungal prophylaxis and combination therapy. Introduction and overview. Clin Infect Dis 2004; 39: S165-S169.
22. Rex JH, Walsh TJ, Sobel JD, Filler SG, Pappas PG, Dismukes WE, Edwards JE. Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. Clin Infect Dis 2000; 30: 662-678.
23. Singh N. Antifungal prophylaxis in solid organ transplant recipients: considerations for clinical trial design. Clin Infect Dis 2004; 39: S200-S206.
24. Winston DJ, Pakrasi A, Bussuttil RW. Prophylactic fluconazole in liver transplant recipients randomized, double-blind, placebo controlled trial. Ann Intern Med 1999; 131: 729-737.